Cocaine use continues to be a major public health problem, yet there are no proven medication treatments for cocaine abuse. Thus cocaine abuse represents an important target for medications development. Recent evidence primarily from preclinical studies suggests that medications which block L-type calcium channels or antagonize the function of the excitatory amino acid (EAA) gaged cation channels permeable to calcium are able to blunt the effects of cocaine. The proposed research investigates whether these medications have similar effects in humans. Three major studies, each evaluating study """""""" effects on behavioral and cardiovascular responses to intranasal cocaine 120 mg/70 kg and cocaine placebo during six laboratory test sessions, are proposed. The first study will determine whether single 60 mg and 90 mg oral doses of the L- type calcium channel blocker nimodipine given 60 minutes prior to cocaine will reduce cocaine effects in human subjects. The second study will determine whether single 120 mg and 240 mg oral doses of the EAA release inhibitor lamotrigine given 120 minutes prior to cocaine will reduce cocaine effects in human subjects. The third study will determine whether subanesthetic intravenous doses of the noncompetitive NMDA type EAA antagonist ketamine administered via a bolus and infusion paradigm will reduce cocaine effects in human subjects. Cocaine will be administered 15 minutes into the 75 minute infusion. Ketamine doses will be based on preliminary data in healthy subjects and a pilot project evaluating the effects of ketamine alone in subjects with a history of cocaine abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009250-03
Application #
5209734
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12
Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7
Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25
Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27
Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71
Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51
Stine, S M; Grillon, C G; Morgan 3rd, C A et al. (2001) Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berl) 154:274-81
Jacobsen, L K; Southwick, S M; Kosten, T R (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-90
Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5

Showing the most recent 10 out of 39 publications